IL15 and familial pancreatic carcinoma: A study revealed that systemic administration of MSCs, which is isolated from human umbilical cord blood and release IL15 (UCMSCs- IL15), to the mouse model of pancreatic cancer might lead to a reduction in the tumor growth and induce survival time through NK and CD8 T cell activation and proliferation (135).